Atlas Capital Advisors Inc. Invests $528,000 in Jazz Pharmaceuticals PLC $JAZZ

Atlas Capital Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the fourth quarter, HoldingsChannel reports. The firm bought 3,107 shares of the specialty pharmaceutical company’s stock, valued at approximately $528,000.

Several other hedge funds have also modified their holdings of the business. Hilltop National Bank acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $36,000. LRI Investments LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $38,000. Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $40,000. Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Truist Financial set a $256.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 9th. Morgan Stanley reaffirmed an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Royal Bank Of Canada upped their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Finally, TD Cowen raised their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Sixteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $246.06.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the transaction, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 11,941 shares of company stock valued at $2,565,339. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $230.59 on Tuesday. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $243.32. The firm has a market cap of $14.49 billion, a price-to-earnings ratio of -11,523.74, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The company’s 50-day moving average is $218.48 and its two-hundred day moving average is $189.25. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.